Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma Sees Silver Lining In Maribavir Failure: Now There’s Cash To Go Bargain Hunting

This article was originally published in The Pink Sheet Daily

Executive Summary

A good candidate would require a limited commercial infrastructure and make use of the company’s knowledge in transplantation, CEO Milano says, trying to redirect attention from the failed antiviral.
Advertisement

Related Content

ViroPharma Gets Good News And Bad News On Cinryze From FDA
ViroPharma Gets Good News And Bad News On Cinryze From FDA
R&D IN BRIEF
R&D IN BRIEF
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
ViroPharma Sets High Pricing For Cinryze, Unveils Promotional Plan

Topics

Advertisement
UsernamePublicRestriction

Register

PS068973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel